138 related articles for article (PubMed ID: 22172098)
1. Possible pathogenic role of the transmembrane isoform of CD160 NK lymphocyte receptor in paroxysmal nocturnal hemoglobinuria.
Giustiniani J; Alaoui SS; Marie-Cardine A; Bernard J; Olive D; Bos C; Razafindratsita A; Petropoulou A; de Latour RP; Le Bouteiller P; Bagot M; Socié G; Bensussan A
Curr Mol Med; 2012 Feb; 12(2):188-98. PubMed ID: 22172098
[TBL] [Abstract][Full Text] [Related]
2. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
[TBL] [Abstract][Full Text] [Related]
3. CD160: a unique activating NK cell receptor.
Le Bouteiller P; Tabiasco J; Polgar B; Kozma N; Giustiniani J; Siewiera J; Berrebi A; Aguerre-Girr M; Bensussan A; Jabrane-Ferrat N
Immunol Lett; 2011 Aug; 138(2):93-6. PubMed ID: 21324341
[TBL] [Abstract][Full Text] [Related]
4. Identification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.
Giustiniani J; Bensussan A; Marie-Cardine A
J Immunol; 2009 Jan; 182(1):63-71. PubMed ID: 19109136
[TBL] [Abstract][Full Text] [Related]
5. Human and mouse mast cells express and secrete the GPI-anchored isoform of CD160.
Ortonne N; Ram-Wolff C; Giustiniani J; Marie-Cardine A; Bagot M; Mecheri S; Bensussan A
J Invest Dermatol; 2011 Apr; 131(4):916-24. PubMed ID: 21191401
[TBL] [Abstract][Full Text] [Related]
6. CD160-activating NK cell effector functions depend on the phosphatidylinositol 3-kinase recruitment.
Rabot M; El Costa H; Polgar B; Marie-Cardine A; Aguerre-Girr M; Barakonyi A; Valitutti S; Bensussan A; Le Bouteiller P
Int Immunol; 2007 Apr; 19(4):401-9. PubMed ID: 17307798
[TBL] [Abstract][Full Text] [Related]
7. Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP.
Hanaoka N; Kawaguchi T; Horikawa K; Nagakura S; Mitsuya H; Nakakuma H
Blood; 2006 Feb; 107(3):1184-91. PubMed ID: 16195329
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
Barakonyi A; Rabot M; Marie-Cardine A; Aguerre-Girr M; Polgar B; Schiavon V; Bensussan A; Le Bouteiller P
J Immunol; 2004 Nov; 173(9):5349-54. PubMed ID: 15494480
[TBL] [Abstract][Full Text] [Related]
9. CD160 is essential for NK-mediated IFN-γ production.
Tu TC; Brown NK; Kim TJ; Wroblewska J; Yang X; Guo X; Lee SH; Kumar V; Lee KM; Fu YX
J Exp Med; 2015 Mar; 212(3):415-29. PubMed ID: 25711213
[TBL] [Abstract][Full Text] [Related]
10. A soluble form of the MHC class I-specific CD160 receptor is released from human activated NK lymphocytes and inhibits cell-mediated cytotoxicity.
Giustiniani J; Marie-Cardine A; Bensussan A
J Immunol; 2007 Feb; 178(3):1293-300. PubMed ID: 17237375
[TBL] [Abstract][Full Text] [Related]
11. The PIG-anchoring defect in NK lymphocytes of PNH patients.
Schubert J; Uciechowski P; Delany P; Tischler HJ; Kolanus W; Schmidt RE
Blood; 1990 Sep; 76(6):1181-7. PubMed ID: 1698101
[TBL] [Abstract][Full Text] [Related]
12. The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection.
Del Rio ML; Nguyen TH; Tesson L; Heslan JM; Gutierrez-Adan A; Fernandez-Gonzalez R; Gutierrez-Arroyo J; Buhler L; Pérez-Simón JA; Anegon I; Rodriguez-Barbosa JI
Transl Res; 2022 Jan; 239():103-123. PubMed ID: 34461306
[TBL] [Abstract][Full Text] [Related]
13. Murine CD160, Ig-like receptor on NK cells and NKT cells, recognizes classical and nonclassical MHC class I and regulates NK cell activation.
Maeda M; Carpenito C; Russell RC; Dasanjh J; Veinotte LL; Ohta H; Yamamura T; Tan R; Takei F
J Immunol; 2005 Oct; 175(7):4426-32. PubMed ID: 16177084
[TBL] [Abstract][Full Text] [Related]
14. BY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expression.
Nikolova M; Marie-Cardine A; Boumsell L; Bensussan A
Int Immunol; 2002 May; 14(5):445-51. PubMed ID: 11978774
[TBL] [Abstract][Full Text] [Related]
15. Engagement of the CD160 activating NK cell receptor leads to its association with CD2 in circulating human NK cells.
Rabot M; Bensussan A; Le Bouteiller P
Transpl Immunol; 2006 Dec; 17(1):36-8. PubMed ID: 17157212
[TBL] [Abstract][Full Text] [Related]
16. CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.
D'Addio F; Ueno T; Clarkson M; Zhu B; Vergani A; Freeman GJ; Sayegh MH; Ansari MJ; Fiorina P; Habicht A
PLoS One; 2013; 8(4):e60391. PubMed ID: 23593209
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
[TBL] [Abstract][Full Text] [Related]
18. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells.
Šedý JR; Bjordahl RL; Bekiaris V; Macauley MG; Ware BC; Norris PS; Lurain NS; Benedict CA; Ware CF
J Immunol; 2013 Jul; 191(2):828-36. PubMed ID: 23761635
[TBL] [Abstract][Full Text] [Related]
19. Altered natural killer cell subset homeostasis and defective chemotactic responses in paroxysmal nocturnal hemoglobinuria.
El-Sherbiny YM; Kelly RJ; Hill A; Doody GM; Hillmen P; Cook GP
Blood; 2013 Sep; 122(11):1887-90. PubMed ID: 23881915
[TBL] [Abstract][Full Text] [Related]
20. Patients with paroxysmal nocturnal hemoglobinuria have a high frequency of peripheral-blood T cells expressing activating isoforms of inhibiting superfamily receptors.
Poggi A; Negrini S; Zocchi MR; Massaro AM; Garbarino L; Lastraioli S; Gargiulo L; Luzzatto L; Notaro R
Blood; 2005 Oct; 106(7):2399-408. PubMed ID: 15956278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
